Targeting HER2 in the treatment of non-small cell lung cancer.

@article{Mar2015TargetingHI,
  title={Targeting HER2 in the treatment of non-small cell lung cancer.},
  author={Nataliya Mar and James J. Vredenburgh and Jeffrey S Wasser},
  journal={Lung cancer},
  year={2015},
  volume={87 3},
  pages={
          220-5
        }
}
Oncogenic driver mutations have emerged as major treatment targets for molecular therapies in a variety of cancers. HER2 positivity has been well-studied in breast cancer, but its importance is still being explored in non-small cell lung cancer (NSCLC). Laboratory methods for assessment of HER2 positivity in NSCLC include immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next generation sequencing (NGS) for gene mutations… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.

  • Clinical lung cancer
  • 2018
VIEW 12 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

  • Journal of experimental & clinical cancer research : CR
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment

Andrei-Tudor Cernomaz, Ina Iuliana Macovei, +7 authors Bogdan- Dragos Grigoriu
  • BMC Pulmonary Medicine
  • 2016
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 57 REFERENCES

New targetable oncogenes in non-small-cell lung cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

I Phase study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2 - dependent and other solid tumors

B Besse, Soria J-C, B Yao
  • J Clin Oncol
  • 2014

Neratinib with or without temsirolimus in patients with non - small cell lung cancer carrying HER 2 somatic mutations : an international randomized phase II study

SM Swain, SB Kim, +3 authors M Campone
  • ESMO Cong
  • 2014

after failure of prior chemotherapy and erlotinib

L Gandhi, R Bahleda, +3 authors SS Pandya
  • 2014